You can see it here.

Download a copy of the the dismissal notice here.

This document relates to this story on Business Insider.

It’s a shame for me personally because Placebo Effect had a monthly readership in the hundreds of thousands, and I broke some important stories in that venue.

I’m a realist, however. If advertisers don’t want to buy ads next to health/drug news, then CBS cannot continue to provide that kind of information. There is no such thing as a free lunch.

I’ve been writing about the drug industry on and off since 2004. Doubtless, at some point in the future, I will once again patrol the pharma beat. But for now, absent a sudden sponsorship of the blog, I’m taking a break.

I’d like to thank all those of you who read the column on a regular basis. I know there were many of you. I read all your emails, and all your comments, and as many tweets as I can. I will miss our correspondence.

Sincerely,

Jim Edwards

Depakote complaint part 2.

Depakote complaint part 3.

Depakote complaint part 4.

These documents relate to this story on BNET.

http://www.bnet.com/search?q=jim+edwards&tag=mantle_skin;content

Grey successfully persuaded New York State Supreme Court in Manhattan to seal the documents in 2006. Unfortunately for Grey, court access for journalists is kind of my “thing.” I knew the ruling was wrong on the law.  It took me four more years to get them unsealed.

This is an extreme example, but it’s an example nonetheless, of how difficult it can be to write stories about the advertising business that don’t show the industry in a flattering light.

I’d like to thank a few people who made this story possible. First, David Schulz of Levin Sullivan Koch & Schulz in New York, who agreed to refer the case to the Yale Law School Media Freedom and Information Access Practicum. Schulz also argued the case before the New York State Appellate Division.

Second, Patrick Kabat and Nabiha Syed who researched and wrote the successful appellate brief. They graduated Yale Law this year.

All of these lawyers represented me pro bono. If you are a large media corporation with a court access issues and an unspent budget for outside legal counsel, these are the lawyers to call.

Here is a Harper’s Index-style list of trivia about how this story came to be published:

• 23: Number of different drafts of this story requested by various editors and lawyers at other publications that were never published.
• 1: Number of drafts requested by editors at BNET.
• 6: Number of years since I first received a tip that the documents existed
• 4: Number of years since the documents were first filed in court.
• 3: Number of business magazines that passed on the story.
• 2: Number of daily newspapers who passed on the story.
• 3: Number of lawyers who told me the story could not be published without a court ruling releasing them to me.
• 0: Percentage of those lawyers who offered to petition the court to get them.
• 3: Number of legal briefs I wrote myself that were unsuccessful in persuading New York State Supreme Court to release the documents.
• 1: Grade out of 10 that I would give the New York State Supreme Court’s pro se services office on a scale measuring “helpfulness.”
• 19: Number of months it took a state court judge to decide not to release the documents.
• 5: Number of months it took the appeals court to overrule the original state court ruling.
• 4: Number of Grey executives or their lawyers who implied or explicitly stated, on and off the record, that I would be sued for publishing this story.
• 5: Number of appeals court judges who agreed unanimously, on all counts, that I was right and Grey was wrong.
• Too many: Number of my friends or family who should have known better than to suggest, however well-intentioned they were, that maybe I ought to just drop it.

For previous readers, however, some things have shuffled around. All my pharmaceutical stuff is here and all my advertising stuff is here. Please update your links, bookmarks and RSS feeds! You’ll notice that BNET Pharma and BNET Advertising have been given trendy new names, “Placebo Effect” and “The Tagline,” respectively. (I argued for “The Pill Popper” for the drug blog, but management didn’t like that one.)

One slight difference is that in the new redesign we’ve temporarily lost access to our automatic comment notification feeds. This means I might be slow or absent in responding to comments that require a response for the next few weeks. So if you spot something that’s flat wrong, email me directly at jim edwards 123 @ hotmail dot com.

Aside from that, not much has changed. I’m still focusing on the biggest, most controversial stories of the day, and trying to draw some management advice out of them. I’d love to get your feedback.